On April 6, 2020, the U.S. Drug Enforcement Agency (“DEA”) made history by descheduling Epidiolex, GW Pharmaceuticals’ anti-epileptic oral solution containing cannabiodiol (“CBD”), thereby removing it from the purview of
Continue Reading DEA Deschedules Cannabinol-Containing Epidiolex
